/ENTO
ENTO Stock - Entero Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.98-9.17%
$0.20 (-9.17%) • Dec 18
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENTO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.96 – $2.00
TARGET (TP)$2.28
STOP LOSS$1.82
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$5.84
52W Low$0.97
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-29,274 | $-106,207 | $-537,400 | $-571,145 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-15,621.274 | $-15,770,827 | $-12,678,066 | $-59,056,888 | $-26,432,768 |
| Net Income | $-18,059,336 | $-15,794,983 | $-14,629,642 | $-58,537,849 | $-32,671,466 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.88 | $-46.96 | $-407.37 | $-27544.98 | $-48255.29 |
Company Overview
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ENTOBeat Rate
50%
Last 10 quarters
Avg Surprise
-38.4%
EPS vs Estimate
Beats / Misses
5/5
Last 12 quarters
Latest EPS
$-0.64
Q4 2025
EPS Surprise History
Q1 24
-32.8%
$-5.35vs$-4.03
Q2 24
+115.6%
$0.38vs$-2.43
Q3 24
-147.7%
$-3.84vs$-1.55
Q4 24
-37.5%
$-1.32vs$-0.96
Q2 25
-536.6%
$-2.61vs$-0.41
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | — | $-0.64 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.14 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.63 | — | — |
Q2 2025 | Apr 4, 2025 | $-0.41 | $-2.61 | -536.6% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.96 | $-1.32 | -37.5% | ✗ MISS |
Q3 2024 | Aug 26, 2024 | $-1.55 | $-3.84 | -147.7% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-2.43 | $0.38 | +115.6% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-4.03 | $-5.35 | -32.8% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-33.60 | $-9.08 | +73.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-20.80 | $-36.89 | -77.4% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-43.90 | $-35.70 | +18.7% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-80.12 | — | — |
Q3 2022 | Sep 30, 2022 | $-421.40 | $378.17 | +189.7% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-2100.00 | $-1041.59 | +50.4% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-2601.07 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-3158.65 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-13667.14 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-4988.40 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-5832.11 | — | — |
Latest News
Entero Therapeutics To Change Its Name To GridAI Technologies And Ticker Symbol To GRDX, Effective December 1
➖ NeutralBenzinga•Nov 28, 2025, 01:02 PM
Entero Therapeutics shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 20, 2025, 04:53 PM
Entero Therapeutics Q3 EPS $(0.64) Up From $(1.77) YoY
📈 PositiveBenzinga•Nov 20, 2025, 12:19 AM
Entero Therapeutics' Grid AI Executes LOI With Hyperscaler AI Data-Center Developer To Deploy Grid AI's Power-Cluster Optimization And Orchestration Platform
📈 PositiveBenzinga•Nov 19, 2025, 01:49 PM
Entero's Grid AI Subsidiary Finalizes Establishment Of US-Based Leadership Team, Preparing For US Expansion
📈 PositiveBenzinga•Nov 13, 2025, 01:40 PM
Entero Therapeutics' Grid AI Announces A LOI To Integrate The LV Grid Engineering Team And Its Intellectual Property Into Grid AI
📈 PositiveBenzinga•Nov 6, 2025, 01:48 PM
Entero Regains Compliance With Nasdaq Listing
📈 PositiveBenzinga•Oct 30, 2025, 10:24 AM
Entero Therapeutics Launches Grid AI Corp. To Revolutionize AI Data Center Power Management And Accelerate Infrastructure Deployment
📈 PositiveBenzinga•Oct 16, 2025, 12:43 PM
Entero Therapeutics Reinvents As Grid Tech Company With Acquisition Of GRID AI, Switching From Biotech To Energy Infrastructure
➖ NeutralBenzinga•Oct 14, 2025, 12:11 PM
ENTO stock has given up its prior gain. Entero Therapeutics shares were trading higher after the company acquired 100% of GRID AI Corp.
➖ NeutralBenzinga•Oct 1, 2025, 10:08 PM
Entero Therapeutics shares are trading higher after the company acquired 100% of GRID AI Corp.
📈 PositiveBenzinga•Oct 1, 2025, 08:07 PM
Entero Therapeutics Acquires GRID AI; GRID Shareholders To Own 82.5% Of ENTO; No Financial Terms Disclosed
📉 NegativeBenzinga•Oct 1, 2025, 08:07 PM
On Sept 3, Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately; On Spet 4 Jason D. Sawyer Appointed As Interim CEO; Paolone Remains Director After Termination
📉 NegativeBenzinga•Sep 9, 2025, 09:05 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 15, 2025, 11:50 PM
Entero Therapeutics jumps on $3M securities offering
➖ NeutralSeeking Alpha•Aug 11, 2025, 12:07 PM
Frequently Asked Questions about ENTO
What is ENTO's current stock price?
Entero Therapeutics, Inc. (ENTO) is currently trading at $1.98 per share. The stock has moved -9.17% today.
What is the analyst price target for ENTO?
No analyst price targets are currently available for this stock.
What sector is Entero Therapeutics, Inc. in?
Entero Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENTO's market cap?
Entero Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ENTO pay dividends?
No, Entero Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLR
Allarity Therapeutics, Inc.
$1.03
Mkt Cap: $0.0B
ASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to ENTO for comparison